Non-Compliance Claim
£5M Claim → £250K Settlement
Future Compliance Licences Only
Client Overview
| Industry | Pharmaceutical / Life Sciences |
| Location | United Kingdom |
| IT Environment | Highly regulated, spanning R&D, manufacturing, and distribution across on-premises servers, private cloud, and hybrid setups |
| Issue | IBM audit with claims exceeding £5 million in non-compliance fees, citing sub-capacity licensing violations, virtualisation policy breaches, and multi-product deployment issues |
| Services Provided | Audit Report Analysis, Internal Software Usage Audit, Strategic IBM Engagement & Negotiation, Licence Optimisation & Future-Proofing |
| Outcome | £5M claim reduced to £250K (95% reduction). Centralised licence management implemented. Zero operational disruptions. Enhanced internal audit processes established. |
The Challenge
A leading pharmaceutical company in the UK faced an IBM audit with claims exceeding £5 million in non-compliance fees. The company's highly regulated IT environment, spanning R&D, manufacturing, and distribution, made managing software licences complex across multiple platforms and deployment models.
IBM's audit findings highlighted alleged non-compliance related to sub-capacity licensing, virtualisation policies, and the use of multiple IBM products across on-premises servers, private cloud environments, and hybrid setups.
The company's internal IT and procurement teams lacked the expertise to interpret and challenge IBM's audit findings effectively. IBM audit claims in regulated industries like pharmaceuticals are particularly high-stakes. The company could not risk operational disruptions to critical R&D, manufacturing, and distribution systems while defending against the audit. Without independent expertise, they faced the prospect of accepting IBM's inflated claim or entering negotiations without understanding which findings were valid and which were based on errors in IBM's calculations.
The Process
Redress Compliance was engaged to manage the complete audit defence, from initial analysis through to final settlement and long-term compliance planning. The engagement followed a structured four-phase approach:
Audit Report Analysis
Began by scrutinising IBM's audit report to identify errors in their calculations and assumptions. Reviewed the company's existing contracts, entitlements, and deployment records to establish an accurate baseline for compliance, separating legitimate compliance gaps from overestimations in IBM's findings.
Internal Software Usage Audit
Conducted a thorough review of software deployments across on-premises servers, private cloud environments, and hybrid setups. Verified usage data with a particular focus on high-risk areas including sub-capacity licensing and processor value unit (PVU) calculations. Identified significant discrepancies between IBM's findings and the company's actual software usage.
Strategic Engagement with IBM
Engaged directly with IBM's audit team to challenge their findings, presenting corrected data and highlighting compliance measures already in place. Leveraged deep understanding of IBM's licensing policies to negotiate favourable dispute resolution terms. Highlighted the pharmaceutical company's critical role in the healthcare sector to build goodwill during the negotiation process.
Optimisation & Future-Proofing
Reallocated unused licences and optimised deployments to align with licensing entitlements, closing remaining compliance gaps without additional purchases where possible. Provided a tailored compliance management plan including regular internal audits and licence tracking tools. Delivered training sessions on IBM licensing requirements for the company's IT and procurement teams to prevent future issues.
Sub-capacity licensing and PVU calculations in virtualised environments are among the most frequent sources of errors in IBM audit reports. IBM's audit methodology often defaults to full physical capacity when ILMT (IBM Licence Metric Tool) data is incomplete or misconfigured, dramatically inflating the apparent non-compliance. By independently verifying actual usage against ILMT data, deployment records, and contractual entitlements, Redress Compliance regularly identifies significant overestimations that can reduce audit claims by 80-95%.
The Outcome
£5M → £250K
The £5 million IBM audit claim was reduced to just £250,000, a 95% reduction. The settlement covered only the cost of additional licences required for future compliance.
Zero Penalties Imposed
No retroactive fees or punitive charges. The final settlement addressed only genuinely required forward-looking licence additions.
Business Continuity Protected
IT operations remained fully uninterrupted throughout the entire audit and negotiation process, ensuring continued focus on critical pharmaceutical research and production.
Compliance Framework Established
Centralised licensing management, enhanced internal audit processes, and IBM licensing training for IT and procurement teams implemented for long-term protection.
IBM's audit felt insurmountable until Redress Compliance stepped in. Their expertise saved us millions and ensured our licensing practices are rock-solid moving forward. They turned a crisis into an opportunity to improve.
Results Summary
| Metric | Detail |
|---|---|
| Initial IBM Audit Claim | £5,000,000 |
| Final Settlement | £250,000 (95% reduction) |
| Total Savings | £4,750,000 |
| Compliance Improvements | Centralised licensing management and enhanced internal audit processes implemented |
| Business Continuity | Zero operational disruptions during negotiations and remediation |
| Future Protection | IBM licensing training delivered to IT and procurement teams; licence tracking tools deployed |
Facing an IBM Audit?
If your organisation is dealing with an IBM software licence review, audit findings, or compliance concerns, contact us today. Our independent IBM licensing experts have helped enterprises reduce audit claims by 80-97%, protecting millions in budget.
IBM Audit Defence Service → Book a ConsultationSee how we have saved enterprises hundreds of millions in IBM audit exposure — real results across industries and geographies. View All IBM Case Studies →
📄 Free IBM Licensing White Papers
Download our in-depth guides on IBM audit defence, PVU licensing, ILMT compliance, and negotiation strategies.
Download Whitepapers →Related IBM Case Studies & Resources
Our IBM Advisory Services
Licensing Assessment
Independent licence reviews & cost optimisation
Audit Defence
Expert defence against IBM Software Licence Reviews
Negotiations
Independent support for IBM renewals & ELAs
ELA Renewals
Optimise IBM Enterprise Licence Agreement renewals